Let's actually
talk about it.
Health information has never been easier to find. Understanding what any of it actually means is another story.
These are deeper conversations about hormones, metabolism, weight, nutrition, prevention, chronic disease, healthy aging and the everyday choices that can change how we feel now—and how we function years from now.
Written so patients can understand it. Detailed enough that healthcare professionals can stay for the conversation too.
Read something useful.
Start with something that matters to you. Click an article and it will open directly below. As we add new conversations, the newest pieces will move into this collection automatically.
Hormone Therapy Got Scary. The Story Was More Complicated.
Keep digging.
New articles will take over the featured cards above, but nothing disappears. Search the full library by topic or browse a category.
Understanding your health changes what you can do with it.
You do not have to become your own doctor.
But you deserve to understand the decisions being made about your body, the evidence behind them and the things you can do to protect your health over time.
Prefer A Quick Answer?If you were an adult woman in the early 2000s, there is a decent chance you heard some version of this: hormone replacement therapy causes breast cancer and heart attacks.
That message did not come out of nowhere. It came from one of the most influential women's-health studies ever conducted—the Women's Health Initiative, or WHI.
The problem is not that the WHI was a bad study. It was an enormously important study.
The problem is what happened when a complicated study became a very simple headline.
First: what was the Women's Health Initiative actually studying?
The WHI hormone trials were designed largely to answer a question that was very popular at the time: could menopausal hormone therapy prevent chronic diseases such as cardiovascular disease in postmenopausal women?
That is important because it is not quite the same question as: “Is hormone therapy reasonable for a healthy 51-year-old who just entered menopause and is waking up drenched in sweat every night?”
Women enrolled in the WHI hormone trials were between 50 and 79, with an average age of approximately 63—considerably older than the average age of natural menopause.
Women with a uterus received oral conjugated equine estrogen plus medroxyprogesterone acetate. Women who had undergone hysterectomy were studied separately and received conjugated equine estrogen alone.
WHI did not test every estrogen, every progesterone, every route of administration or every woman at every age.
It studied specific regimens in a population that included many women who were substantially older than patients who typically begin hormone therapy today for menopause symptoms.
Then 2002 happened.
The estrogen-plus-progestin portion of WHI was stopped early after investigators found that the overall pattern of risks and benefits did not support using that regimen for chronic-disease prevention.
There were increases in outcomes including breast cancer, coronary events, stroke and venous thromboembolism, along with benefits such as fewer fractures.
The message that reached much of the public was considerably less nuanced:
Prescribing fell dramatically. Women discontinued therapy. Clinicians became understandably hesitant.
And for years, many women with substantial menopause symptoms avoided treatment because an individualized risk conversation had essentially become a yes-or-no question.
Except the estrogen-only trial didn't tell the same story.
This is one of the details lost when we simply say, “the WHI showed hormones cause breast cancer.”
It did not show one universal breast-cancer effect across both hormone trials.
In long-term randomized follow-up, women with prior hysterectomy who had been assigned conjugated equine estrogen alone had lower breast-cancer incidence and lower breast-cancer mortality than women assigned placebo.
In contrast, the estrogen-plus-medroxyprogesterone group showed an increase in breast-cancer incidence in long-term follow-up.
That does not mean estrogen is an anti-cancer medication or that it can be prescribed indiscriminately.
It means something much more useful: the formulation matters.
Timing matters too.
As investigators continued analyzing WHI data, it became increasingly clear that age and time since menopause matter when evaluating hormone therapy.
Modern menopause guidance generally considers the benefit-risk balance most favorable for appropriately selected symptomatic women who are younger than 60 or within approximately 10 years of menopause onset, assuming they do not have contraindications.
Starting systemic hormone therapy at 51 is not biologically identical to initiating it for the first time at 72.
So is hormone therapy safe?
I don't love that question because almost nothing useful in medicine is simply “safe” or “unsafe.”
The clinically useful question is:
For healthy women near the menopause transition who have bothersome hot flashes or night sweats and do not have contraindications, hormone therapy remains the most effective treatment for vasomotor symptoms.
Hormone therapy also helps prevent bone loss while it is being used.
Route matters: swallowing estrogen is not the same as wearing it.
Oral estrogen passes through the liver before reaching systemic circulation. Transdermal estrogen—a patch, gel or spray—is absorbed through the skin and avoids the same first-pass hepatic exposure.
Observational data suggest transdermal estrogen may carry less venous thromboembolism risk than oral estrogen, although route comparisons have limitations.
Again: “estrogen” is not one single exposure.
Progesterone is not the same thing as every progestin.
A woman with an intact uterus who receives systemic estrogen generally also needs adequate endometrial protection.
In WHI, the combination arm used medroxyprogesterone acetate, a synthetic progestin.
Today, clinicians may also use micronized progesterone, which is chemically identical to endogenous human progesterone.
Different progestogens may have different biological and clinical effects.
Better is not the same thing as magical.
Now let's clean up the word “bioidentical.”
“Bioidentical” simply means the hormone molecule has the same chemical structure as the hormone produced by the human body.
Estradiol can be bioidentical.
Micronized progesterone can be bioidentical.
And bioidentical hormones can be available as commercially manufactured products or through a compounding pharmacy.
Where compounded hormones can be especially useful
Bodies do not always cooperate with the handful of dose increments available in a commercially manufactured medication.
One patient may need a strength between two standard doses. Another may tolerate one delivery system poorly. Someone else may need a specific ingredient avoided or a formulation adjusted around an individual treatment plan.
That is where compounding can be genuinely useful: it gives us another way to personalize the prescription.
Personalized does not mean we ignore evidence or normal physiologic targets. It means we can sometimes tailor the medication more precisely when commercially available choices do not fit well.
The value of compounding is not that the medication becomes magically “more natural.” The value is flexibility.
Different dose. Different delivery system. Different combination when clinically appropriate. A prescription built around the patient instead of forcing every patient into the same few boxes.
Bioidentical versus synthetic is not really a winner-versus-loser question.
Some synthetic hormones have excellent evidence and decades of clinical use.
Bioidentical estradiol and progesterone also offer useful options and are commonly used in modern menopause care.
What matters clinically is not whether the word natural sounds nicer.
It is the actual molecule, dose, route, indication, patient history and treatment goal.
What changed recently?
In February 2026, the FDA approved labeling changes to six menopausal hormone-therapy products that removed cardiovascular disease, breast-cancer and probable-dementia statements from the boxed warning.
That is a significant shift in the way risk is being communicated.
It does not mean every woman should take hormones.
It does mean the conversation has finally become more precise than the message many women heard twenty years ago.
What the evidence actually allows us to say
The conversation I wish women had been given from the beginning
Menopause is not a hormone-deficiency disease that every woman must medicate.
It is also not a test of character where you earn extra credit for suffering through severe symptoms without treatment.
Some women barely notice the transition. Others stop sleeping, develop significant vasomotor symptoms, experience painful genitourinary changes, lose sexual function, struggle with mood or cognitive complaints, or simply stop feeling like themselves.
Those women deserve a serious conversation about their options.
The goal is to stop frightening appropriate women away from them—and to stop pretending there is one correct formulation for every woman.
That middle ground is less dramatic.
It is also much closer to good medicine.
Want to read the evidence yourself?
If the scale says you lost 40 pounds, that is only part of the story. The next question is: what did you lose?
Weight-loss medications have changed obesity treatment dramatically. GLP-1 and GLP-1/GIP medications can produce an amount of weight loss that was difficult to achieve with lifestyle treatment alone for many people.
That is a very good thing.
But rapid weight loss creates a problem that deserves more attention: your body does not remove only fat.
Weight and fat are not synonyms.
Body weight includes fat, muscle, organs, bone, water and everything else that happens to be inside you when you step on a scale.
During meaningful weight loss, some lean mass is usually lost along with fat mass.
Studies of GLP-1-based therapies show that the majority of weight lost is generally fat, but reductions in lean mass can occur as well.
The goal is less excess fat while maintaining as much strength, muscle and physical capacity as reasonably possible.
Why should we care about muscle?
Muscle is not decorative.
It helps us stand up, climb stairs, stabilize joints, maintain independence, regulate glucose and recover from illness.
This becomes even more important as we age because adults already tend to lose muscle mass and strength over time.
So what do we do differently?
First, we stop treating nutrition during weight loss as: eat as little as possible because the medication makes that easy.
Adequate protein matters. Enough overall nutrition matters.
Second, we give muscle a reason to stay.
Walking is excellent for health, but resistance exercise provides a different physiologic signal—one specifically asking muscle to produce force.
I care about the 70-year-old version of you too.
A successful weight-loss plan should make that future person lighter when appropriate, but also strong enough to live their life.
The number on the scale is useful.
It is not the entire outcome.
Back-to-school health is not a supplement aisle. Most of the things that help children function well are considerably less exciting—and much more important.
August has a way of turning every parent into a logistics coordinator.
Health often gets reduced to buying a multivitamin and hoping nobody brings home the first respiratory virus of the year.
We can do better than that.
Start with sleep.
Sleep affects far more than whether a child is cranky in the morning. It affects attention, behavior, mental health, academic performance and physical health.
Food does not have to be perfect to be useful.
We can aim for useful sources of protein, fruits and vegetables when possible, adequate nutrition for growth and activity, and meals the child will actually eat.
Movement matters for brains too.
Physical activity supports cardiovascular health, metabolic health, bone health, fitness and emotional wellbeing.
What about vitamins?
Vitamins are essential. That does not automatically mean every child needs a complicated supplement regimen.
Supplementation makes sense when diet, medical history, dietary restriction or an actual clinical need makes it useful.
There is a difference between being proactive about your health and turning your body into a spreadsheet that can never quite earn an A.
Optimization is one of the most seductive words in modern wellness.
A reference range is not a ranking system.
Laboratory ranges are interpreted in context. Being closer to one end does not automatically mean you are healthier.
More testing creates more findings.
Run enough tests on a healthy person and eventually something will fall outside a reference interval.
Sometimes that matters. Sometimes it creates another test, another supplement, another bill and more anxiety without improving health.
“Can we measure it?” is not the same question as “Will knowing this improve someone's health?”
The boring metrics are still incredibly powerful.
Blood pressure. Tobacco exposure. Glucose regulation. Lipids. Physical activity. Sleep. Nutrition. Mental health. Cancer screening.
They do not produce an impressive wall of biomarkers.
They still account for an enormous amount of the health we are trying to protect.
High blood pressure often feels like absolutely nothing. That is exactly why it gets underestimated.
If hypertension reliably caused a terrible headache every time it started damaging blood vessels, we would probably control it much better.
Usually it doesn't.
Blood pressure is force.
When blood pressure remains elevated over time, the heart, brain, kidneys and blood vessels are exposed to increased stress.
One ugly reading is not always hypertension.
Pain, anxiety, caffeine, exercise, an incorrect cuff size and even body position can change a reading.
Good diagnosis depends on good measurement.
Lifestyle treatment is real treatment.
Nutrition, sodium, activity, weight when relevant, alcohol, sleep and stress all matter.
Medication can matter too.
The goal is to live well.
Preventive care is not an appointment where we tell you to eat vegetables, order “annual labs” and see you again in twelve months.
The point of preventive medicine is to identify meaningful risk before it becomes a much bigger problem.
Screening is not random testing.
A useful screening test should find something at a point where earlier detection actually improves outcomes and where benefits outweigh harms.
Age matters. So does risk.
Screening plans depend on age, history, family history, tobacco exposure, chronic disease and previous results.
Some of the most important screening is remarkably unexciting.
Blood pressure. Diabetes risk. Cardiovascular risk. Evidence-based cancer screening. Vaccination. Tobacco use. Mental health.
We are making decisions today for the version of you who has not needed the hospital yet.
Sometimes the smartest thing you can do for your skin is stop attacking it.
Skin care has developed a productivity problem.
If one active is good, surely four actives, an acid, a scrub and a retinoid must be better.
Your skin barrier is not decorative.
The outer epidermis limits water loss and helps protect deeper tissue from the outside environment.
Exfoliation is controlled damage.
That can be useful. The problem is believing skin improves in direct proportion to how irritated we can make it.
And sunscreen belongs in the health conversation.
Ultraviolet exposure contributes to photoaging and pigmentation, but it also contributes to skin-cancer risk.
Protecting your skin is preventive health that happens to make skin look better over time too.
Sometimes the same behavior serves both. Skin protection is one of those times.